Altimmune, Inc. (NASDAQ:ALT) marched up 87.06% compared to a 52-week low price of $1.7. The shares were last seen trading -6.47% lower, taking the closing price at $3.18 on 4/12/2019. At a recent session, the prices were hovering between $3.14 and $3.48. This company shares are 214.47% off its target price of $10 and the current market capitalization stands at $43.85M. The recent change has given its price a 5.17% lead over SMA 50 and -91.23% deficit over its 52-week high. The stock witnessed 15.64% gains, 18.66% gains and -30.72% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ALT’s volatility during a week at 8.21% and during a month it has been found around 8.7%.Altimmune, Inc. (ALT) Top Holders
Institutional investors currently hold around $3 million or 7.2% in ALT stock. Look at its top three institutional owners: Sabby Management, Llc owns $757 thousand in Altimmune, Inc., which represents roughly 1.73% of the company’s market cap and approximately 25.23% of the institutional ownership. Similar statistics are true for the second largest owner, Renaissance Technologies Llc, which owns 194,506 shares of the stock are valued at $619 thousand. The third largest holder is Vanguard Group Inc, which currently holds $351 thousand worth of this stock and that ownership represents nearly 0.8% of its market capitalization.
At the end of December reporting period, 14 institutional holders increased their position in Altimmune, Inc. (NASDAQ:ALT) by some 744,065 shares, 8 decreased positions by 166,050 and 5 held positions by -118,770. That puts total institutional holdings at 791,345 shares, according to SEC filings. The stock grabbed 11 new institutional investments totaling 551,859 shares while 6 institutional investors sold out their entire positions totaling 162,167 shares.Altimmune, Inc. (NASDAQ:ALT) Insider Trades
Multiple company employees have indulged in significant insider trading. Altimmune, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Pisano Wayne has acquired 2,000 shares of Altimmune, Inc. (ALT) in the trading session dated Oct. 09, 2018. These shares are worth $9,180 and were traded at $4.59 each. The SEC filing shows that Enright William performed a purchase of 1,300 shares. The President and CEO added these shares by way of transaction on May. 25, 2018. The company’s shares were assimilated at $0.51 per share worth to an investment of some $663 to the account of Enright William.
Director, SCHAFFER DERACE L, purchased 97,410 common shares of Altimmune, Inc. (ALT) in the open market. In a transaction dated Dec. 29, 2017, the shares were bought at an average price of $1.92, giving away a sum of $187,027. After this purchase, 601,846 common shares of ALT are directly owned by the insider, with total stake valued at $1,913,870.
In the transaction dated Dec. 29, 2017, a great number of shares acquired came courtesy the Director; SAYARE MITCHEL added a total of 5,100 shares at an average price of $1.95, amounting to approximately $9,945. The insider now directly owns 32,650 shares worth $103,827.Altimmune, Inc. (ALT) Analyst Guide
Not many analysts have released their opinion on Altimmune, Inc. (NASDAQ:ALT), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].